0000899243-22-036303.txt : 20221117 0000899243-22-036303.hdr.sgml : 20221117 20221117211212 ACCESSION NUMBER: 0000899243-22-036303 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221116 FILED AS OF DATE: 20221117 DATE AS OF CHANGE: 20221117 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nacht Mariana CENTRAL INDEX KEY: 0001831310 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38707 FILM NUMBER: 221400366 MAIL ADDRESS: STREET 1: 65 HAYDEN AVENUE STREET 2: 2ND FLOOR CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LogicBio Therapeutics, Inc. CENTRAL INDEX KEY: 0001664106 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 471514975 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 65 HAYDEN AVE STREET 2: 2ND FLOOR CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617-245-0399 MAIL ADDRESS: STREET 1: 65 HAYDEN AVE STREET 2: 2ND FLOOR CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-11-16 1 0001664106 LogicBio Therapeutics, Inc. LOGC 0001831310 Nacht Mariana C/O LOGICBIO THERAPEUTICS, INC. 65 HAYDEN AVE, FLOOR 2 LEXINGTON MA 02421 0 1 0 0 Chief Scientific Officer Stock Option (right to buy) 0.70 2022-11-16 4 D 0 100000 D 2032-03-01 Common Stock 100000 0 D The options were granted on March 1, 2022. The options were scheduled to vest over four years: 25% of the options were scheduled to vest on the first anniversary of the grant date with the remaining 75% vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service with the LogicBio Therapeutics, Inc. (the "Company") on each vesting date. Pursuant to the Agreement and Plan of Merger, dated as of October 3, 2022, by and among the Company, Alexion Pharmaceuticals, Inc. ("Parent") and Camelot Merger Sub, Inc. ("Merger Sub"), on November 16, 2022 (the "Effective Time"), Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Parent, and, at the Effective Time, each option was cancelled pursuant to the terms of the Merger Agreement; provided, that each option with a per share exercise price equal to or greater than $2.07 was automatically cancelled for no consideration. For more information see the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company with the United States Securities and Exchange Commission on October 18, 2022. /s/ Frederic Chereau, as Attorney-in-Fact 2022-11-17